Anti-depressant vortioxetine launched in IndiaDecember 13, 2018
Lundbeck launched vortioxetine (Brintellix) in India for the treatment of patients suffering from major depressive disorder (MDD), following approval from Drug Controller General of India (DCGI).
Vortioxetine is a novel multimodal antidepressant which has been specifically designed to inhibit serotonin reuptake and modulate serotonergic receptor activity of the neurons in the brain of affected patients.
It has demonstrated significant efficacy in reducing the mood symptoms in adult patients with depression as measured by traditional scales like MADRS or HAMD.
The drug also improves cognitive performance in adult patients with depression, as measured with neuropsychological tests. Cognitive symptoms are part of the diagnostic criteria for depression and include the ability to concentrate, make decisions and the ability to remember, said Lundbeck.